Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...

DelveInsight's, “Erosive Esophagitis Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive Esophagitis pipeline landscape. It covers the ...

Please provide your email address to receive an email when new articles are posted on . A: This 52-year-old man with presumed gastroesophageal reflux disease, erosive esophagitis grade D, is referred ...

Background: Evidence regarding the association between alcohol consumption and the gastro-esophageal reflux disease (GERD) spectrum has been conflicting. We examined the association between alcohol ...

Vonoprazan is an oral small molecule potassium-competitive acid blocker. The Food and Drug Administration (FDA) has accepted for review the New Drug Application for vonoprazan as a treatment for the ...

The report provides a detailed analysis of the current erosive esophagitis marketed drugs and late-stage pipeline drugs. BROOKLYN, NY, UNITED STATES, July 11, 2025 /EINPresswire / -- According to the ...

throat The application is supported by data from the pivotal phase 3 PHALCON-EE trial which compared the efficacy and safety of vonoprazan to lansoprazole in patients with erosive esophagitis. The New ...

How Do I Take Voquezna? Voquezna is an oral tablet that is taken once daily for GERD or erosive esophagitis and twice daily for H. pylori. Voquezna can be taken with or without food. Your doctor will ...

The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...

Los Angeles, CA – New clinical data demonstrated, for the first time in a prospective study, a direct relationship between controlling gastric (or stomach) acid and healing erosive esophagitis caused ...